Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: The CRESCEND study

Human Psychopharmacology

Volumn 26, Issue 1, 2011, Pages 41-50

  Kim, Jae Min ^a   Kim, Sung Wan ^a   Stewart, Robert ^b   Kim, Seon Young ^a   Yoon, Jin Sang ^a   Jung, Sung Won ^c   Lee, Min Soo ^d   Yim, Hyeon Woo ^e   Jun, Tae Youn ^e  

^a Chonnam National University Medical School   (South Korea)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Keimyung University   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

Author keywords

Anxiety; Depression; Korea; Parasuicide; Remission

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

AGE; ANXIETY; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL GLOBAL IMPRESSION SCALE; COMBINATION CHEMOTHERAPY; DEPRESSION; DEPRESSIVE PSYCHOSIS; DISABILITY; DYSTHYMIA; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENDER; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MARRIAGE; MEDICAL HISTORY; MENTAL DISEASE; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; RELIGION; REMISSION; SOCIAL AND OCCUPATIONAL FUNCTIONAL ASSESSMENT SCALE; SOUTH KOREA; SUICIDE ATTEMPT; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION DISABILITY ASSESSMENT SCHEDULE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; REPUBLIC OF KOREA; SEX FACTORS; SUICIDE, ATTEMPTED; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953238716     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1168     Document Type: Article

References (41)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, American Psychiatric Press, Inc.: Washington, DC.
2. Cipriani A, Furukawa TA, Salanti G, et al. 2009. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373: 746-758.
3. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. 2002. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 16: 4-13.
4. Denninger JW, Papakostas GI, Mahal Y, et al. 2006. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics 47: 348-352.
5. Eipping-Jordan J, Ustun TB, Assessment, Classification and Epidemiology Group. 2000. The WHODAS II: levelling the playing field for all disorders. WHO Mental Health Bull 6: 5-6.
6. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. 1997. Major depressive subtypes and treatment response. Biol Psychiatry 42: 568-576. (Pubitemid 27425475)
7. Fava M, Alpert JE, Carmin CN, et al. 2004. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 34: 1299-1308.
8. Fava M, Rush AJ, Alpert JE, et al. 2008. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 165: 342-351. (Pubitemid 351704490)
9. First MB, Spitzer RL, Gibbon M, Williams JB. 1996. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders Research Version (SCID-I). New York State Psychiatric Institute, Biometrics Research: New York.
10. Frank E, Prien RF, Jarrett RB, et al. 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48: 851-855.
11. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health: Rockville.
12. Hamilton MA. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
13. Hamilton MA. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
14. Hirschfeld RM, Russell JM, Delgado PL, et al. 1998. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 59: 669-675. (Pubitemid 29068312)
15. Hirschfeld RM, Montgomery SA, Aguglia E, et al. 2002. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63: 826-837.
16. Horesh N, Nachshoni T, Wolmer L, Toren P. 2009. A comparison of life events in suicidal and nonsuicidal adolescents and young adults with major depression and borderline personality disorder. Compr Psychiatry 50: 496-502.
17. Howland RH, Rush AJ, Wisniewski SR, et al. 2009. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend 99: 248-260.
18. Iosifescu DV, Nierenberg AA, Alpert JE, et al. 2003. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 160: 2122-2127. (Pubitemid 39619604)
19. Joffe RT, Bagby RM, Levitt A. 1993. Anxious and nonanxious depression. Am J Psychiatry 150: 1257-1258. (Pubitemid 23218913)
20. Judd LL, Paulus MJ, Schettler PJ, et al. 2000. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 157: 1501-1504.
21. Jung SH. 2005. The Socioeconomic Burden of Suicide and Depression in Korea. National Center for Mental Health Research and Education. Available at: http://nimh.snmh.go.kr/bbs/zboard.php?id=publication&-page=1&sn1= &divpage=1amp;sn=off&ss=on&sc=on&select-arrange= -subject&desc=asc&no=2 [Accessed 25 March 2008].
22. Keller MB, Gelenberg AJ, Hirschfeld RM, et al. 1998. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 59: 598-607. (Pubitemid 28555421)
23. Keller MB, McCullough JP, Klein DN, et al. 2000. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342: 1462-1470. (Pubitemid 30318269)
24. Kessler RC, Berglund P, Demler O, et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105. (Pubitemid 37432885)
25. Kim JM, Stewart R, Glozier N, et al. 2005. Physical health, depression and cognitive function as correlates of disability in an older Korean population. Int J Geriatr Psychiatry 20: 160-167. (Pubitemid 40277895)
26. Korea National Statistical Office. 2006. Annual report on the cause of death statistics of 2005. Available at: http://kostat.go.kr/board-notice/ BoardAction.do?method=view&board-id=144&seq=10amp;num=10&parent-num= 0&page=1&page-name=all-list&kind-id=2&catgrp=nso2009&catid1= k04-0000&catid2=k04b-0000&catid3=&catid4= [Accessed 18 September 2006].
27. Kornstein SG, Schatzberg AF, Thase ME, et al. 2000. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157: 1445-1452.
28. Lee JY, Cho MJ, Kwon JS. 2006. Global Assessment of Functioning Scale and Social and Occupational Functioning Scale. Korean J Psychopharmacol 17: 122-127.
29. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. 1987. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic treated patients. Acta Psychiatr Scand 76: 1-100. (Pubitemid 17115352)
30. Mann JJ, Arango VA, Avenevoli S, et al. 2009. Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry 65: 556-563.
31. Mann JJ, Ellis SP, Waternaux CM, et al. 2008. Classification trees distinguish suicide attempters in major psychiatric disorders: a model of clinical decision making. J Clin Psychiatry 69: 23-31. (Pubitemid 351281993)
32. Mann JJ, Waternaux C, Haas GL, et al. 1999. Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 156: 181-189. (Pubitemid 29077107)
33. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. 2007. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370: 851-858. (Pubitemid 47362344)
34. Oquendo MA, Galfalvy H, Russo S, et al. 2004. Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am J Psychiatry 161: 1433-1441. (Pubitemid 38989097)
35. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. 1995. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25: 1171-1180.
36. Rush AJ, Trivedi MH, Wisniewski SR, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917. (Pubitemid 44807782)
37. Thase ME, Entsuah R, Cantillon M, Kornstein SG. 2005. Relative anti-depressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health 14: 609-616. (Pubitemid 41488679)
38. Trivedi MH, Rush AJ, Wisniewski SR, et al. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
39. Warden D, Rush AJ, Wisniewski SR, et al. 2009. Income and attrition in the treatment of depression: a STAR*D report. Depress Anxiety 26: 622-633.
40. Yi JS, Bae SO, Ahn YM, et al. 2005. Validity and reliability of the Korean version of the Hamilton Depression Rating Scale (K-HDRS). J Korean Neuropsychiatr Assoc 44: 456-465.
41. Young EA, Kornstein SG, Marcus SM, et al. 2009. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res 43: 503-511.